1
/
of
1
Elabscience
SKU:PKSH033909
Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc)
Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc), a cutting-edge product designed to revolutionize the field of immunology. This meticulously engineered recombinant protein showcases exceptional functionality and versatility, making it an indispensable tool for researchers and scientists alike.
Crafted with utmost precision, this product embodies the fusion of the Human Leukocyte Ig-Like Receptor B2 (LILRB2), also known as ILT4 or CD85d, with the constant region of the immunoglobulin G (IgG) molecule, denoted as C-Fc. This fusion results in a chimeric protein that combines the unique binding properties of LILRB2 with the enhanced stability and effector functions conferred by the Fc region.
The Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) offers an array of applications in various research domains. Its ability to interact with a diverse range of ligands, including major histocompatibility complex (MHC) class I molecules and other immunoglobulins, enables comprehensive investigations into immune regulation, cellular signaling, and immune cell interactions.
Moreover, this product's fusion with the Fc region empowers it with effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These attributes open up new avenues for studying immune responses, therapeutic antibody development, and immunotherapeutic strategies.
The Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) is meticulously manufactured using state-of-the-art recombinant DNA technology, ensuring exceptional purity, stability, and bioactivity. Rigorous quality control measures guarantee the consistency and reliability of each batch, providing researchers with the utmost confidence in their experimental outcomes.
In summary, the Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) represents a groundbreaking advancement in immunological research. Its fusion of LILRB2 with the Fc region offers unparalleled functionality and opens up new possibilities for investigating immune regulation, cellular signaling, and therapeutic interventions. Embrace this innovative tool and unlock the potential of your research endeavors.
Crafted with utmost precision, this product embodies the fusion of the Human Leukocyte Ig-Like Receptor B2 (LILRB2), also known as ILT4 or CD85d, with the constant region of the immunoglobulin G (IgG) molecule, denoted as C-Fc. This fusion results in a chimeric protein that combines the unique binding properties of LILRB2 with the enhanced stability and effector functions conferred by the Fc region.
The Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) offers an array of applications in various research domains. Its ability to interact with a diverse range of ligands, including major histocompatibility complex (MHC) class I molecules and other immunoglobulins, enables comprehensive investigations into immune regulation, cellular signaling, and immune cell interactions.
Moreover, this product's fusion with the Fc region empowers it with effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These attributes open up new avenues for studying immune responses, therapeutic antibody development, and immunotherapeutic strategies.
The Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) is meticulously manufactured using state-of-the-art recombinant DNA technology, ensuring exceptional purity, stability, and bioactivity. Rigorous quality control measures guarantee the consistency and reliability of each batch, providing researchers with the utmost confidence in their experimental outcomes.
In summary, the Recombinant Human Leukocyte Ig-Like Receptor B2/LILRB2/ILT4/CD85d (C-Fc) represents a groundbreaking advancement in immunological research. Its fusion of LILRB2 with the Fc region offers unparalleled functionality and opens up new possibilities for investigating immune regulation, cellular signaling, and therapeutic interventions. Embrace this innovative tool and unlock the potential of your research endeavors.
Share
